BRAF/MEK inhibition reduces tumor burden and upregulates MHC-I/tumor antigens; inhibits ERK-MAPK-CXCL8 axis → enhances BBB permeability & T cell infiltration; PD-L1 blockade restores effector T cell function. Here, MAP2K7 is linked to neoplasm.